Pneumagen Highlights Broad-Spectrum Antiviral Activity of First-in-Class Intranasal Drug Neumifil in New Publication
03. Juli 2024 04:00 ET
|
Pneumagen Ltd
Pneumagen has previously reported positive results from both Phase 1 and a clinical proof of concept Phase 2 Human Influenza Challenge study demonstrating the potential of NeumifilNew preclinical...
Pneumagen Presents Positive Phase 2 Influenza Human Challenge Study data on Neumifil, its Broad-Spectrum Antiviral Drug, at the American Thoracic Society (ATS) 2024 Conference
23. Mai 2024 07:00 ET
|
Pneumagen Ltd
Neumifil delivers statistically significant reductions in influenza symptomatic infection rate, symptom severity and viral loadStrategy to advance clinical development of Neumifil to be based on...
Pneumagen to Present Phase 2 Clinical Data on Neumifil, its Broad-Spectrum Antiviral, Intranasal Drug for Viral Respiratory Tract Infections, at ATS 2024
02. Mai 2024 07:00 ET
|
Pneumagen Ltd
Data to be presented in oral and ePoster presentations St Andrews, UK – 2 May 2024 - Pneumagen, a clinical stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal drug for...
Pneumagen Announces Successful Clinical Proof of Concept for its Broad-Spectrum Antiviral Neumifil in Phase 2 Influenza Human Challenge Study
02. Oktober 2023 04:00 ET
|
Pneumagen Ltd
Study achieves primary & secondary endpoints in a randomised, placebo-controlled challenge studyNeumifil delivers a statistically significant reduction in both symptomatic infection rate &...
Pneumagen raises £8m to accelerate Phase 2 clinical development of Neumifil for the prevention & treatment of viral respiratory tract infections
01. Juni 2023 04:00 ET
|
Pneumagen Ltd
Neumifil is being developed for the prevention and treatment of virus induced exacerbations in patients with respiratory diseaseAdvancing Neumifil into a Phase 2b clinical study due to start in 2024 ...
Pneumagen further strengthens IP protection for lead product Neumifil with granting of US composition of matter patent
18. April 2023 04:00 ET
|
Pneumagen Ltd
Neumifil is a novel intranasal spray being developed to provide those at-risk with an easy to use, broad-spectrum antiviral treatment to reduce and prevent respiratory disease exacerbations caused by...